Clear All
11398 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
70121-2484-01 70121-2484 Bortezomib BORUZU 3.5 mg/1.4mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Sep 27, 2024 In Use
83831-0104-05 83831-0104 Palonosetron Posfrea 0.075 mg/1.5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sep 30, 2024 Sep 30, 2024 No Longer Used
70518-4191-00 70518-4191 PredniSONE PredniSONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sep 30, 2024 In Use
70518-4191-01 70518-4191 PredniSONE PredniSONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sep 30, 2024 In Use
70518-4191-02 70518-4191 PredniSONE PredniSONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sep 30, 2024 In Use
83831-0105-01 83831-0105 Palonosetron Posfrea 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sep 30, 2024 In Use
57237-0078-50 57237-0078 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sep 30, 2024 In Use
57237-0078-01 57237-0078 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sep 30, 2024 In Use
57237-0077-50 57237-0077 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sep 30, 2024 In Use
57237-0077-01 57237-0077 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sep 30, 2024 In Use
00480-9259-08 00480-9259 Octreotide Acetate Octreotide Acetate 3.33 mg/ml Hormonal Therapy Somatostatin Analog Intramuscular Oct 1, 2024 In Use
72603-0325-01 72603-0325 Pemetrexed disodium Pemetrexed 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Oct 1, 2024 In Use
72603-0254-01 72603-0254 Everolimus EVEROLIMUS 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct 1, 2024 In Use
00781-3312-95 00781-3312 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct 1, 2024 In Use
72603-0255-01 72603-0255 Everolimus EVEROLIMUS 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct 1, 2024 In Use
00480-9262-08 00480-9262 Octreotide Acetate Octreotide Acetate 3.33 mg/ml Hormonal Therapy Somatostatin Analog Intramuscular Oct 1, 2024 In Use
72603-0425-01 72603-0425 Pemetrexed disodium Pemetrexed 500.0 mg/50mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Oct 1, 2024 In Use
00781-3415-95 00781-3415 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct 1, 2024 In Use
72603-0256-01 72603-0256 Everolimus EVEROLIMUS 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct 1, 2024 In Use
70518-4195-00 70518-4195 Anastrozole Anastrozole 1.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Oct 1, 2024 In Use
72603-0257-01 72603-0257 Everolimus EVEROLIMUS 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct 1, 2024 In Use
82804-0157-04 82804-0157 Dexamethasone Dexamethasone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct 9, 2024 In Use
00781-3531-91 00781-3531 Paclitaxel Paclitaxel 100.0 mg/20mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct 9, 2024 In Use
68788-8749-06 68788-8749 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Oct 11, 2024 In Use
68788-8749-09 68788-8749 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Oct 11, 2024 In Use

Found 11398 results — Export these results